AstraZeneca to Expand Frederick Biologics Manufacturing Center, Add 300 Jobs

AstraZeneca is expanding its biologics manufacturing center in Frederick. The global biopharmaceutical company plans to invest more than $200 million to increase production capacity at the facility.

AstraZeneca is expanding its biologics manufacturing center in Frederick. The global biopharmaceutical company plans to invest more than $200 million to increase production capacity at the facility.

The Frederick manufacturing center is FDA licensed. It is a large-scale cell culture production facility, where AstraZeneca manufactures pediatric medication and other investigational biologic products. According to the company, the Frederick manufacturing center, with its hundreds of thousands of square feet of administrative, production, warehouse, laboratory and utility space, is the largest asset in its global portfolio of properties.

The more than $200 million expansion project will add 40,000 additional square feet of manufacturing, laboratory and administrative space to the facility. It will help support AstraZeneca’s maturing pipeline and will allow the company to keep pace with the growing demand for the development and use of biologics.

“Biologics are an important part of AstraZeneca’s overall capabilities, in addition to our strengths in small molecules and protein engineering,” Andrew D. Skibo, regional vice president of biologics supply for AstraZeneca, said in a statement. “Our global biologics research and development arm, MedImmune, has a robust pipeline of more than 120 biologics, including more than 30 in clinical development. The expansion of our Frederick facility will support the progression of drug candidates across our core therapeutic areas, ultimately aiding us in our efforts to make a meaningful difference in the lives of patients through scientific leadership and innovative new treatments.”

The project will also create a total of 300 new jobs. AstraZeneca moved 300 jobs to Gaithersburg last year, from Wilmington, Delaware. It currently has 3,100 people working in the state of Maryland.

“We’re very pleased by AstraZeneca’s demonstrable commitment to our local workforce and to our growing biotech community,” Frederick City Mayor Randy McClement added. “This expansion will help bring even more high-caliber life science jobs and career opportunities to Frederick and the surrounding region.”

AstraZeneca plans to start construction on the project in December. It expects to finish it in mid-2017.

Photo credit: AstraZeneca